Does the media refer more to CYTK or RVMD?

In the previous week, Revolution Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for Revolution Medicines and 8 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.63 beat Cytokinetics' score of 0.43 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TEVA or CYTK?

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 8 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat Cytokinetics' score of 0.43 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 15 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CYTK or ONC?

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 116.23 -$784.96M -$6.84 N/A BeOne Medicines $5.34B 6.24 $286.93M $4.47 68.00

Does the media refer more to CYTK or ONC?

In the previous week, Cytokinetics and Cytokinetics both had 8 articles in the media. BeOne Medicines' average media sentiment score of 0.77 beat Cytokinetics' score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or CYTK more profitable?

Moderna has a net margin of -143.55% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Cytokinetics -784.02% N/A -52.86%

Does the media favor MRNA or CYTK?

In the previous week, Moderna had 16 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Moderna and 8 mentions for Cytokinetics. Moderna's average media sentiment score of 0.82 beat Cytokinetics' score of 0.43 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ROIV or CYTK?

In the previous week, Cytokinetics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Cytokinetics' score of 0.43 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Cytokinetics (CYTK) Competitors

$82.24 -2.63 (-3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$81.47 -0.77 (-0.93%)

As of 07:47 PM Eastern

Compare

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Cytokinetics compare to Revolution Medicines?

Cytokinetics (NASDAQ:CYTK) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Cytokinetics currently has a consensus target price of $99.90, indicating a potential upside of 21.47%. Revolution Medicines has a consensus target price of $144.00, indicating a potential downside of 21.72%. Given Cytokinetics' higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

94.3% of Revolution Medicines shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for Revolution Medicines and 8 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.63 beat Cytokinetics' score of 0.43 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Revolution Medicines	N/A	-83.22%	-59.06%

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A
Revolution Medicines	$11.58M	3,377.18	-$1.13B	-$7.07	N/A

Summary

Revolution Medicines beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Cytokinetics (NASDAQ:CYTK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, suggesting a potential upside of 29.94%. Cytokinetics has a consensus price target of $99.90, suggesting a potential upside of 21.47%. Given Teva Pharmaceutical Industries' higher probable upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 8 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat Cytokinetics' score of 0.43 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.14	$1.41B	$1.33	24.17
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Cytokinetics' net margin of -784.02%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Cytokinetics	-784.02%	N/A	-52.86%

Summary

Teva Pharmaceutical Industries beats Cytokinetics on 12 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to BeOne Medicines?

Cytokinetics (NASDAQ:CYTK) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

48.6% of BeOne Medicines shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Cytokinetics presently has a consensus price target of $99.90, indicating a potential upside of 21.47%. BeOne Medicines has a consensus price target of $391.38, indicating a potential upside of 28.76%. Given BeOne Medicines' higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Cytokinetics and Cytokinetics both had 8 articles in the media. BeOne Medicines' average media sentiment score of 0.77 beat Cytokinetics' score of 0.43 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Cytokinetics' net margin of -784.02%. BeOne Medicines' return on equity of 12.06% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BeOne Medicines	8.94%	12.06%	6.69%

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00

Summary

BeOne Medicines beats Cytokinetics on 12 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Moderna?

Moderna (NASDAQ:MRNA) and Cytokinetics (NASDAQ:CYTK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Moderna had 16 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Moderna and 8 mentions for Cytokinetics. Moderna's average media sentiment score of 0.82 beat Cytokinetics' score of 0.43 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	11 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Moderna presently has a consensus target price of $38.27, indicating a potential downside of 42.89%. Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 21.47%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Moderna has a net margin of -143.55% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Cytokinetics	-784.02%	N/A	-52.86%

Cytokinetics has lower revenue, but higher earnings than Moderna. Cytokinetics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Moderna beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Cytokinetics (NASDAQ:CYTK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential downside of 2.66%. Cytokinetics has a consensus price target of $99.90, suggesting a potential upside of 21.47%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Roivant Sciences has higher earnings, but lower revenue than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.70 beat Cytokinetics' score of 0.43 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -3,629.19%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Cytokinetics	-784.02%	N/A	-52.86%

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.56B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-12.02	20.85	27.15	24.26
Price / Sales	116.23	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	-15.26	8.49	10.75	6.29
Net Income	-$784.96M	$23.83M	$3.58B	$330.66M
7 Day Performance	-3.89%	-3.18%	-2.10%	-2.41%
1 Month Performance	17.23%	6.31%	3.32%	-0.64%
1 Year Performance	122.21%	52.74%	28.17%	20.09%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.4822 of 5 stars	$82.24 -3.1%	$99.90 +21.5%	+129.3%	$10.56B	$88.04M	N/A	250
RVMD Revolution Medicines	1.9557 of 5 stars	$189.99 +0.4%	$142.33 -25.1%	+391.5%	$40.23B	$11.58M	N/A	250
TEVA Teva Pharmaceutical Industries	4.8031 of 5 stars	$35.29 +1.9%	$41.78 +18.4%	+100.3%	$39.83B	$17.26B	26.53	33,950	Positive News Analyst Downgrade
ONC BeOne Medicines	4.6744 of 5 stars	$309.46 +4.0%	$390.00 +26.0%	+19.3%	$32.66B	$5.34B	66.59	12,000	Insider Trade Gap Up
MRNA Moderna	1.8577 of 5 stars	$81.80 +2.6%	$37.13 -54.6%	+102.9%	$31.65B	$1.94B	N/A	4,700	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Summary

How does Cytokinetics compare to BeOne Medicines?

Summary

How does Cytokinetics compare to Moderna?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Cytokinetics compare to Revolution Medicines?

Which has more risk & volatility, CYTK or RVMD?

Do analysts rate CYTK or RVMD?

Do insiders and institutionals believe in CYTK or RVMD?

Does the media refer more to CYTK or RVMD?

Is CYTK or RVMD more profitable?

Which has higher valuation & earnings, CYTK or RVMD?

Summary

How does Cytokinetics compare to Teva Pharmaceutical Industries?

Do insiders & institutionals hold more shares of TEVA or CYTK?

Do analysts prefer TEVA or CYTK?

Which has more risk & volatility, TEVA or CYTK?

Does the media prefer TEVA or CYTK?

Which has stronger earnings & valuation, TEVA or CYTK?

Is TEVA or CYTK more profitable?

Summary

How does Cytokinetics compare to BeOne Medicines?

Do insiders and institutionals have more ownership in CYTK or ONC?

Which has more risk and volatility, CYTK or ONC?

Do analysts prefer CYTK or ONC?

Does the media refer more to CYTK or ONC?

Is CYTK or ONC more profitable?

Which has stronger earnings & valuation, CYTK or ONC?

Summary

How does Cytokinetics compare to Moderna?

Which has more risk & volatility, MRNA or CYTK?

Does the media favor MRNA or CYTK?

Do analysts prefer MRNA or CYTK?

Is MRNA or CYTK more profitable?

Which has preferable earnings & valuation, MRNA or CYTK?

Do insiders & institutionals believe in MRNA or CYTK?

Summary

How does Cytokinetics compare to Roivant Sciences?

Do analysts recommend ROIV or CYTK?

Which has preferable valuation & earnings, ROIV or CYTK?

Does the media prefer ROIV or CYTK?

Which has more volatility and risk, ROIV or CYTK?

Do institutionals and insiders hold more shares of ROIV or CYTK?

Is ROIV or CYTK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools